How come no one is talking about CGTX?
CGTX announced phase 3 trial data with multiple near-term catalysts lined up in June, including the H.C. Wainwright Summit, Annual Shareholder Meeting, and FDA Written Minutes on June 19-20, which the author identifies as the primary catalyst. The phase 3 design is public and 3,000 institutional investors have been briefed, positioning the stock for potential upside as these catalysts approach.